Clinical trial / 2022
Celery seed extract was safe and improved blood pressure, fasting blood sugar, lipid profiles, and liver/kidney markers in hypertensive patients.
In a triple-blind, placebo-controlled crossover trial, 51 hypertensive patients received either celery seed capsules (1.34 g extract daily) or placebo for 4 weeks alongside usual medications. Celery seed extract was safe, reduced blood pressure, and decreased FBS from 108.53 to 97.96 mg/dL (p < 0.01). Significant reductions were seen in BUN (3.43 mg/dL), SCr (0.075 mg/dL), SGPT (4.08 U/L), SGOT (3.03 U/L), TC (16.37 mg/dL), TG (16.22 mg/dL), and LDL (11.84 mg/dL), along with an increase in HDL of 2.52 mg/dL (all p < 0.05 or p < 0.001). No significant changes were found in blood cells or serum electrolytes; the study was limited by a small sample size.
- Study type
- Randomized, triple-blind, placebo-controlled, cross-over clinical trial
- Who was studied
- 51 hypertensive patients
- What was measured
- Safety, blood pressure, fasting blood sugar, lipid profile, liver and kidney function markers
THE PAPER
Safety evaluation and biochemical efficacy of celery seed extract (Apium Graveolens) capsules in hypertensive patients: a randomized, triple-blind, placebo-controlled, cross-over, clinical trial.
Shayani Rad M, Moohebati M, MohammadEbrahimi S, Motamedshariaty VS, Mohajeri SA. Inflammopharmacology, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.